Skip to main content Accessibility help

Seco-limonoid derived from Raputia heptaphylla promotes the control of cutaneous leishmaniasis in hamsters (Mesocricetus auratus)



The rational search of novel bioactive molecules against pathogens with immunomodulatory activity is presently one of the most significant approaches to discover and design new therapeutic agents for effective control of infectious diseases, such as the infection caused by Leishmania parasites. In the present study, we evaluated the therapeutic efficacy of the recently characterized immunomodulatory compound 11α,19β-dihydroxy-7-acetoxy-7-deoxoichangin, a seco-limonoid derived from the bark of Raputia heptaphylla (Pittier) using: (1) peritoneal macrophages and (2) Mesocricetus auratus hamsters infected with Leishmania (V.) panamensis and Leishmania (L.) amazonensis. We observed the ability of this seco-limonoid to induce the effective control of the parasite either in vitro [determining an effective concentration 50 (EC50) of 59 µ m at the infection model] and in vivo (inducing clinical improvement or even cure in infected animals treated compared with the groups of animals treated with vehicle solution or meglumine antimoniate).


Corresponding author

*Corresponding author: Pharmacy Department, Faculty of Sciences, Universidad Nacional de Colombia, Kr 45 # 26–85, Bogota, Colombia. E-mail:


Hide All
Abramoff, M., Magalhaes, P. and Ram, S. (2004). Image processing with ImageJ. Biophotonics International 11, 3642.
Alvar, J., Vélez, I. D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., den Boer, M. and WHO Leishmaniasis Control Team (2012). Leishmaniasis Worldwide and Global Estimates of Its Incidence. PloS ONE 7, 112.
AVMA (2007). AVMA Guidelines on Euthanasia (Formerly Report of the AVMA Panel on Euthanasia), pp. 1112. American Veterinary Medical Association.
Awasthi, A., Mathur, R. K. and Saha, B. (2004). Immune response to Leishmania infection. Indian Journal of Medical Research 119, 238258.
Batista, R., Silva Ade, J. Jr. and de Oliveira, A. B. (2009). Plant-derived antimalarial agents: new leads and efficient phytomedicines. Part II. Non-alkaloidal natural products. Molecules 14, 30373072.
Berman, J., Bryceson, A. D., Croft, S., Engel, J., Gutteridge, W., Karbwang, J., Sindermann, H., Soto, J., Sundar, S. and Urbina, J. A. (2006). Miltefosine: issues to be addressed in the future. Transactions of the Royal Society of Tropical Medicine & Hygiene 100 (Suppl 1), S41S44.
Bey, E. and Harington, J. (1971). Cytotoxic effects of some mineral dusts on Syrian hamster peritoneal macrophages. The Journal of Experimental Medicine 135, 11491169.
Clem, A. (2010). A current perspective on leishmaniasis. Journal of Global Infectious Diseases 2, 124126.
Coy Barrera, C. A., Coy Barrera, E. D., Granados Falla, D. S., Delgado Murcia, G. and Cuca Suarez, L. E. (2011). seco-limonoids and quinoline alkaloids from Raputia heptaphylla and their antileishmanial activity. Chemical and Pharmaceutical Bulletin 59, 855859.
Croft, S. L., Seifert, K. and Yardley, V. (2006 a). Current scenario of drug development for leishmaniasis. Indian Journal of Medical Research 123, 399410.
Croft, S. L., Sundar, S. and Fairlamb, A. H. (2006 b). Drug resistance in leishmaniasis. Clinical Microbiology Reviews 19, 111126.
de Carvalho, P. B. and Ferreira, E. I. (2001). Leishmaniasis phytotherapy. Nature's leadership against an ancient disease. Fitoterapia 72, 599618.
Delgado, J., Macias, J., Pineda, J. A., Corzo, J. E., Gonzalez-Moreno, M. P., de la Rosa, R., Sanchez-Quijano, A., Leal, M. and Lissen, E. (1999). High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. The American Journal of Tropical Medicine and Hygiene 61, 766769.
Dorlo, T. P., Balasegaram, M., Beijnen, J. H. and de Vries, P. J. (2012). Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. Journal of Antimicrobial Chemotherapy 67, 25762597.
El-On, J. (2009). Current status and perspectives of the immunotherapy of leishmaniasis. The Israel Medical Association Journal 11, 623628.
Flecknell, P. (1996). Laboratory Animal Anaesthesia, 2nd Edn. Academic Press, New York.
Githua, M., Hassanali, A., Keriko, J., Murilla, G., Ndungu, M. and Nyagah, G. (2010). New antitrypanosomal tetranotriterpenoids from Azadirachta indica . African Journal of Traditional, Complementary, and Alternative Medicines 7, 207213.
Granados-Falla, D., Coy-Barrera, C., Cuca, L. and Delgado, G. (2013). seco-limonoid 11α,19β-dihydroxy-7-acetoxy-7-deoxoichangin promotes the resolution of Leishmania panamensis infection. Advances in Bioscience and Biotechnology 4, 304315.
Hay, A. E., Ioset, J. R., Ahua, K. M., Diallo, D., Brun, R. and Hostettmann, K. (2007). Limonoid orthoacetates and antiprotozoal compounds from the roots of Pseudocedrela kotschyi . Journal of Natural Products 70, 913.
Henao, H. H., Osorio, Y., Saravia, N. G., Gomez, A. and Travi, B. (2004). [Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application]. Biomedica 24, 393402.
Mansueto, P., Vitale, G., Di Lorenzo, G., Rini, G. B., Mansueto, S. and Cillari, E. (2007). Immunopathology of leishmaniasis: an update. International Journal of Immunopathology and Pharmacology 20, 435445.
Meheus, F., Balasegaram, M., Olliaro, P., Sundar, S., Rijal, S., Faiz, M. A. and Boelaert, M. (2010). Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Neglected Tropical Diseases 4, e818.
Mougneau, E., Altare, F., Wakil, A. E., Zheng, S., Coppola, T., Wang, Z. E., Waldmann, R., Locksley, R. M. and Glaichenhaus, N. (1995). Expression cloning of a protective Leishmania antigen. Science 268, 563566.
Mougneau, E., Bihl, F. and Glaichenhaus, N. (2011). Cell biology and immunology of Leishmania . Immunological Reviews 240, 286296.
Newman, D. J. and Cragg, G. M. (2007). Natural products as sources of new drugs over the last 25 years. Journal of Natural Products 70, 461477.
Nylen, S. and Gautam, S. (2010). Immunological perspectives of leishmaniasis. Journal of Global Infectious Diseases 2, 135146.
O'Brien, J., Wilson, I., Orton, T. and Pognan, F. (2000). Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. European Journal of Biochemistry 267, 54215426.
Pulido, S. A., Munoz, D. L., Restrepo, A. M., Mesa, C. V., Alzate, J. F., Velez, I. D. and Robledo, S. M. (2012). Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs. Acta Tropica 122, 3645.
Robledo, S. M., Puerta, J. A., Munoz, D. L., Guardo, M. and Velez, I. D. (2006). Efficacy and tolerance of pentamidine for treatment of cutaneous leishmaniasis caused by L. (V) panamensis in Colombia. Biomedica 26 (Suppl. 1), 188193.
Robledo, S., Carrillo, L., Daza, A., Restrepo, A., Muñoz, D., Tobón, J., Murillo, J., López, A., Ríos, C., Mesa, C., Upegui, Y., Valencia-Tobón, A., Mondragón-Shem, K., Rodríguez, B. and ID, V. (2012). Cutaneous leishmaniasis in the dorsal skin of hamsters: a useful model for the screening of antileishmanial drugs. Journal of Visualized Experiments e3533, 19.
Rosas, L. V. (2005). Phytochemistry, chemosystematic and searching of new antichagasic and antileishmaniasis drugs: study of Raputia praetermissa (Rutaceae). Tesis Universidad Federal de San Carlos – Brasil San Carlos, 280 p.
Santos, D. O., Coutinho, C. E., Madeira, M. F., Bottino, C. G., Vieira, R. T., Nascimento, S. B., Bernardino, A., Bourguignon, S. C., Corte-Real, S., Pinho, R. T., Rodrigues, C. R. and Castro, H. C. (2008). Leishmaniasis treatment—a challenge that remains: a review. Parasitology Research, 103, 110.
Schneider, C., Rasband, W. and Eliceiri, K. (2012). NIH image to ImageJ: 25 years of image analysis. Nature Methods 9, 671675.
TDR (2004). Report of the Scientific Working Group meeting on Leishmaniasis. Tropical Disease Research – World Health Organization, Geneva.
WHO (2005). Report of a WHO Informal Consultation on Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis. pp. 25. Rome, Italy.
WHO (2010). Control of the Leishmaniasis (Report of a meeting of the WHO Expert Committee on the Control of Leishmaniasis). Geneva.



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed